Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701)
- 7 November 2015
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (3) , 557-565
Abstract
The aim of this study was to explore whether a combination of S-1 and paclitaxel offers any benefit over paclitaxel alone to patients pretreated by S-1.Keywords
This publication has 23 references indexed in Scilit:
- Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002)Gastric Cancer, 2011
- Race and ethnicity correlate with survival in patients with gastric adenocarcinomaAnnals of Oncology, 2009
- Chemotherapy for Gastric Cancer that Recurs After Adjuvant Chemotherapy with S-1Japanese Journal of Clinical Oncology, 2008
- Phase II Study of a Combination of S-1 and Paclitaxel in Patients with Unresectable or Metastatic Gastric CancerOncology, 2008
- Effects of Combined Administration of DPD-Inhibitory Oral Fluoropyrimidine, S-1, Plus Paclitaxel on Gene Expressions of Fluoropyrimidine Metabolism-Related Enzymes in Human Gastric XenograftsAnnals of Surgical Oncology, 2008
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trialThe Lancet Oncology, 2008
- Phase II Study of a Combination of Irinotecan and S-1 in Patients with Advanced Gastric Cancer (OGSG0002)Oncology, 2007
- Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric CancerClinical Cancer Research, 2006
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III TrialJournal of Clinical Oncology, 2003